Loading clinical trials...

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers | Clinical Trials | Clareo Health

RECRUITINGPHASE1

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

NCT07162441•Korea United Pharm. Inc.

View on ClinicalTrials.gov

Summary

This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subjects aged 19 years or older at the time of screening.
•Subjects with a body weight greater than 50 kg (≥45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg/m² at screening.
•(BMI (kg/m²) = weight (kg) / height (m)²)
•Subjects with no clinically significant congenital or chronic diseases, pathological symptoms or findings at screening.
•Subjects determined by the principal investigator to be suitable for diagnostic procedures and electrocardiogram assessments
•Subjects who agree to use an effective method of contraception (excluding hormonal agents) recognized as appropriate in clinical trials from the first administration of the investigational drug until 14 days after the last administration, together with their spouse or partner.
•Subjects who have provided written informed consent after receiving a full explanation and demonstrating an understanding of the purpose, procedures, and characteristics of this clinical trial and the investigational drug.

Exclusion Criteria

•Subjects with clinically significant diseases or a history of conditions involving the digestive, cardiovascular, endocrine, respiratory, hematologic/oncologic infectious, renal/genitourinary, psychiatric/neurologic, musculoskeletal, immune, otorhinolaryngologic, dermatologic, or ophthalmologic systems.
•Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) or gastrointestinal disease that may affect drug absorption.
•Subjects who have taken drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose, or drugs that may interfere with this clinical trial within 10 days before the first dose
•Subjects who have participated in another clinical trial or bioequivalence study and received an investigational drug within 6 months before the first administration.
•Subjects who have donated whole blood or blood components within 2 weeks, or received a blood transfusion within 4 weeks before the first administration.
•Subjects who meet any of the following criteria within 1 month before the first dose:
•* Average alcohol consumption exceeding 21 drinks/week for men
•* Average alcohol consumption exceeding 14 drinks/week for women
•(1 drink = 50 mL soju, 30 mL liquor, or 250 mL beer)
•* Smoking more than 20 cigarettes/day on average
+1 more criteria

Locations (1)

H plus Yangji Hospital

Seoul, Gwanak-gu, South Korea

Key Dates

Start Date

August 12, 2025

Primary Completion Date

September 30, 2025

Completion Date

March 1, 2026

Last Updated

September 9, 2025

Enrollment

ESTIMATED participants

Conditions

Dyslipidemia

Interventions

treatment A

DRUG

treatment B

DRUG

treatment C

DRUG

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

NCT07238556

HypertensionDyslipidemia+3 more

View study

RECRUITING

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

NCT06314919

Primary HypercholesterolemiaMixed Dyslipidemia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

Inclusion Criteria

Exclusion Criteria

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Effect of Ezetimibe on Gut Microbiota